
    
      The study consists of three parts: dose-escalation of RO7284755 as a single agent (Part 1),
      dose-escalation of RO7284755 in combination with atezolizumab (Part 2), and extension of
      RO7284755 as a single agent and/or in combination with atezolizumab (Part 3).
    
  